Standout Papers

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus P... 2003 2026 2010 2018 2.4k
  1. Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer (2008)
    Giorgio V. Scagliotti, Purvish Parikh et al. Journal of Clinical Oncology
  2. Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer (2003)
    Masahiro Fukuoka, Seiji Yano et al. Journal of Clinical Oncology
  3. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial (2016)
    Louis Fehrenbacher, Alexander I. Spira et al. The Lancet
  4. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016)
    Silvia Novello, Fabrice Barlési et al. Annals of Oncology
  5. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2017)
    Pieter E. Postmus, Keith M. Kerr et al. Annals of Oncology
  6. Phenotype molding of stromal cells in the lung tumor microenvironment (2018)
    Diether Lambrechts, Els Wauters et al. Nature Medicine
  7. Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial (2007)
    U. Gatzemeier, A Płużańska et al. Journal of Clinical Oncology
  8. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study (2012)
    Pasi A. Jänne, Alice T. Shaw et al. The Lancet Oncology
  9. CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer (2018)
    Thanyanan Reungwetwattana, Kazuhiko Nakagawa et al. Journal of Clinical Oncology
  10. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study (2018)
    Fabrice Barlési, Johan Vansteenkiste et al. The Lancet Oncology
  11. Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC (2019)
    Jhanelle E. Gray, Augusto Villegas et al. Journal of Thoracic Oncology
  12. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆ (2021)
    Anne‐Marie C. Dingemans, Martin Früh et al. Annals of Oncology

Immediate Impact

4 by Nobel laureates 17 from Science/Nature 282 standout
Sub-graph 1 of 13

Citing Papers

Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
2024 Standout
A systems view of the vascular endothelium in health and disease
2024 Standout

Works of Johan Vansteenkiste being referenced

Phenotype molding of stromal cells in the lung tumor microenvironment
2018 Standout
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
2016 Standout

Author Peers

Author Last Decade Papers Cites
Johan Vansteenkiste 12602 12892 2814 4267 167 18.0k
Keith M. Kerr 9456 10917 3256 3253 180 16.9k
Martin Reck 13773 13035 3440 4270 327 19.6k
Alan Sandler 17654 15323 3260 5788 162 23.4k
Lesley Seymour 13446 13259 3715 5180 256 21.7k
Igor Bondarenko 12964 8783 3459 3220 303 17.1k
Naiyer A. Rizvi 10797 7606 2182 3473 274 14.6k
Vera Hirsh 14466 13967 2752 4798 196 19.4k
Thierry Le Chevalier 8049 9812 2268 3570 243 15.2k
Ji‐Youn Han 9442 8002 2096 2992 255 12.8k
Silvia Novello 11250 12614 3483 4845 457 18.5k

All Works

Loading papers...

Rankless by CCL
2026